90%Confidence
0Views
FDASource
2026-04-11Date
Summary
A third Class II recall for Teva's Octreotide Acetate (30 mg) confirms widespread sterility failures across multiple dosages, signaling severe quality control breakdowns. This may result in significant product shortages and increased regulatory fines for Teva.
Actionable: Review Teva's quality assurance protocols and consider reducing exposure to their injectable products until resolved.
AI Confidence: 90%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now